Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Icelandic founder mutation BRCA2 999del5: analysis of expression.

Breast cancer research : BCR - 1 Jan 2004

Mikaelsdottir Evgenia K, Valgeirsdottir Sigridur, Eyfjord Jorunn E, Rafnar Thorunn

Abstract excerpt

INTRODUCTION: A founder mutation in the BRCA2 gene (BRCA2 999del5) accounts for 7-8% of female breast cancers and for 40% of male breast cancers in Iceland. If expressed, the mutant gene would encode a protein consisting of the first 256 amino acids of the BRCA2 protein. The purpose of this study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylcysteine
Share to Cysteine Endopeptidases
Share to Founder Effect

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iceland

Share to Molecular Weight

Share to Multienzyme Complexes

Share to Proteasome Endopeptidase Complex

Share to RNA, Neoplasm

Source

Open in PubMed Open full text

Identifiers

PMID: 15217494
DOI: 10.1186/bcr785
PMCID: PMC468616

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15217494-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Icelandic founder mutation BRCA2 999del5: analysis of expression.PMID 15217494Read ↗

The effect of a single BRCA2 mutation on cancer in Iceland.Semantic proximity Read ↗

Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.Semantic proximity Read ↗

Population-based study of risk of breast cancer in carriers of BRCA2 mutation.Semantic proximity Read ↗

cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.Semantic proximity Read ↗

A low proportion of BRCA2 mutations in Finnish breast cancer families.Semantic proximity Read ↗

Study of a single BRCA2 mutation with high carrier frequency in a small population.Semantic proximity Read ↗

A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing.Semantic proximity Read ↗

Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5' end of the BRCA1 gene.Semantic proximity Read ↗

Establishment of three human breast epithelial cell lines derived from carriers of the 999del5 BRCA2 Icelandic founder mutation.Semantic proximity Read ↗

Genetic modulation of RNA splicing rescues BRCA2 function in mutant cells.Semantic proximity Read ↗

A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.Semantic proximity Read ↗

The BARD1 Cys557Ser variant and breast cancer risk in Iceland.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.